Literature DB >> 24716825

Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research.

William W Stoops1, Craig R Rush.   

Abstract

Despite concerted efforts to identify a pharmacotherapy for managing stimulant use disorders, no widely effective medications have been approved. Innovative strategies are necessary to develop successful pharmacotherapies for stimulant use disorders. This manuscript reviews human laboratory studies and clinical trials to determine whether one such strategy, use of combination pharmacotherapies, holds promise. The extant literature shows that combination pharmacotherapy produced results that were better than placebo treatment, especially with medications shown to have efficacy as monotherapies. However, many studies did not compare individual constituents to the combination treatment, making it impossible to determine whether combination treatment is more effective than monotherapy. Future research should systematically compare combined treatments with individual agents using medications showing some efficacy when tested alone.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24716825      PMCID: PMC4017926          DOI: 10.1586/17512433.2014.909283

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  78 in total

Review 1.  Agonist replacement therapy for cocaine dependence: a translational review.

Authors:  Craig R Rush; William W Stoops
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms.

Authors:  Kyle M Kampman; Charles Dackis; Kevin G Lynch; Helen Pettinati; Carlos Tirado; Peter Gariti; Thorne Sparkman; Michal Atzram; Charles P O'Brien
Journal:  Drug Alcohol Depend       Date:  2006-05-11       Impact factor: 4.492

3.  Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans.

Authors:  C R Rush; W D Essman; C A Simpson; R W Baker
Journal:  J Clin Psychopharmacol       Date:  2001-06       Impact factor: 3.153

Review 4.  Efficacy of psychostimulant drugs for cocaine dependence.

Authors:  Xavier Castells; Miguel Casas; Clara Pérez-Mañá; Carlos Roncero; Xavier Vidal; Dolors Capellà
Journal:  Cochrane Database Syst Rev       Date:  2010-02-17

5.  A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence.

Authors:  Harold C Urschel; Larry L Hanselka; Michael Baron
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

6.  Bromocriptine-desipramine protocol in treatment of cocaine addiction.

Authors:  A J Giannini; W Billett
Journal:  J Clin Pharmacol       Date:  1987-08       Impact factor: 3.126

Review 7.  Anticonvulsants for cocaine dependence.

Authors:  S Minozzi; L Amato; M Davoli; M Farrell; A A R L Lima Reisser; P P Pani; M Silva de Lima; B Soares; S Vecchi
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 8.  Glutamate systems in cocaine addiction.

Authors:  Peter W Kalivas
Journal:  Curr Opin Pharmacol       Date:  2004-02       Impact factor: 5.547

Review 9.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

Review 10.  Polypharmacy and bipolar disorder: what's personality got to do with it?

Authors:  G S Sachs; A T Peters; L Sylvia; H Grunze
Journal:  Int J Neuropsychopharmacol       Date:  2013-09-26       Impact factor: 5.176

View more
  17 in total

1.  The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine.

Authors:  Anushree N Karkhanis; Thomas J R Beveridge; Bruce E Blough; Sara R Jones; Mark J Ferris
Journal:  Drug Alcohol Depend       Date:  2016-06-25       Impact factor: 4.492

Review 2.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

3.  Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission.

Authors:  Emily R Hankosky; Heather M Bush; Linda P Dwoskin; Daniel R Harris; Darren W Henderson; Guo-Qiang Zhang; Patricia R Freeman; Jeffery C Talbert
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

4.  The effects of amphetamine, butorphanol, and their combination on cocaine self-administration.

Authors:  Mark A Smith; Michael M Pennock; Elizabeth G Pitts; Katherine L Walker; Kimberly C Lang
Journal:  Behav Brain Res       Date:  2014-08-12       Impact factor: 3.332

5.  Sex differences in the reduction of impulsive choice (delay discounting) for cocaine in rats with atomoxetine and progesterone.

Authors:  John R Smethells; Natashia L Swalve; Lynn E Eberly; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2016-06-20       Impact factor: 4.530

6.  Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?

Authors:  Laura Brandt; Thomas Chao; Sandra D Comer; Frances R Levin
Journal:  Addiction       Date:  2020-09-28       Impact factor: 6.526

7.  Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses.

Authors:  Aaron C Lim; Erica N Grodin; Rejoyce Green; Alexandra Venegas; Lindsay R Meredith; Kelly E Courtney; Nathasha R Moallem; Philip Sayegh; Edythe D London; Lara A Ray
Journal:  Am J Drug Alcohol Abuse       Date:  2020-04-28       Impact factor: 3.829

8.  Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection.

Authors:  Jared Lee; Ji-Young Lee; Christina S Meade; Michael Cohn; Antonio Chahine; Samantha E Dilworth; Jessica F Magidson; Hetta Gouse; Dietmar Fuchs; Adam W Carrico
Journal:  J Neurovirol       Date:  2020-07-29       Impact factor: 2.643

9.  Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.

Authors:  William W Stoops; Erika Pike; Lon R Hays; Paul E Glaser; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2014-11-29       Impact factor: 3.533

Review 10.  How to study sex differences in addiction using animal models.

Authors:  Marilyn E Carroll; Wendy J Lynch
Journal:  Addict Biol       Date:  2016-06-26       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.